期刊文献+

Efficacy and safety of ecabet sodium on functional dyspepsia:A prospective,double-blinded,randomized,multi-center controlled trial 被引量:3

Efficacy and safety of ecabet sodium on functional dyspepsia:A prospective,double-blinded,randomized,multi-center controlled trial
下载PDF
导出
摘要 AIM: To compare ecabet sodium and cimetidine in relieving symptoms of functional dyspepsia. METHODS: We performed a multi-center, prospective, randomized, double-blinded controlled trial to compare the clinical efficacy of ecabet sodium and cimetidine in patients with functional dyspepsia. Two-hundred and seventy-two patients with dyspeptic symptoms fulfilling the Rome-II criteria were enrolled from 7 centers. In the study group (115 patients), 1.5 g ecabet sodium was given twice a day. In the control group (121 patients), 400 mg cimetidine was given twice a day. Symptoms and parameters of quality of life were analyzed at baseline, 3, 14, and 28 d after initiating the treatment. RESULTS: Two-hundred and thirty-six patients completed the clinical trial. After 4 wk of treatment, the rates of improvement in patients with dyspeptic symptoms were not different between two groups (77.4% in the ecabet group and 79.3% in the cimetidine group, respectively, P 〉 0.05). Likewise, the rates of symptomatic improvement were not different at 3 d and 14 d. The parameters of quality of life did not change significantly during the study period in both groups. There was no clinically significant adverse event in both groups. 瞄准:在减轻机能性消化不良的症状比较 ecabet 钠和 cimetidine。方法:我们执行了一个多中心,未来,使随机化,双 blinded 控制了试用在病人把 ecabet 钠和 cimetidine 的临床的功效与机能性消化不良作比较。二 -- 有完成 Rome-II 标准的消化不良的症状的 172 个病人从 7 个中心被注册。在学习组(115 个病人) , 1.5 g ecabet 钠一天被给两次。在控制组(121 个病人) , 400 mg cimetidine 一天被给两次。生命的质量的症状和参数在基线被分析,在开始治疗以后的 3, 14,和 28 d。结果:二 -- 136 个病人完成了临床的试用。在治疗的 4 wk 以后,在有消化不良的症状的病人的改进的率不在二个组之间是不同的(77.4% 在 ecabet 组织,分别地, 79.3% 在 cimetidine 组织 P > 0.05 ) 。同样,征兆的改进的率不在 3 d 和 14 d 是不同的。生命的质量的参数没在两个组在学习时期期间显著地变化。在两个组没有临床上重要的不利事件。结论:在有机能性消化不良的病人, ecabet 钠与 cimetidine 有类似的临床的功效。
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第17期2756-2761,共6页 世界胃肠病学杂志(英文版)
关键词 Functional dyspepsia Ecabet sodium CIMETIDINE 钠元素 功能性消化不良 甲氰咪胍 抗消化性溃疡药
  • 相关文献

参考文献4

  • 1Poong-Lyul Rhee,Young-Ho Kim,Hee Jung Son,Jae J. Kim,Kwang Cheul Koh,Seung Woon Paik,Jong Chul Rhee,Kyoo Wan Choi.Evaluation of Individual Symptoms Cannot Predict Presence of Gastric Hypersensitivity in Functional Dyspepsia[J].Digestive Diseases and Sciences.2000(8)
  • 2Takafumi Ichikawa,Kazuhiko Ishihara,Hiroaki Hayashida,Hiromi Hiruma,Katsunori Saigenji,Kyoko Hotta.Effects of Ecabet Sodium, a Novel Gastroprotective Agent, on Mucin Metabolism in Rat Gastric Mucosa[J].Digestive Diseases and Sciences.2000(3)
  • 3Mine Kinoshita,Hajime Tamaki.Possible Mechanism of Increase in Gastric Mucosal PGE2 and PGI2 Generation Induced by Ecabet Sodium, a Novel Gastroprotective Agent[J].Digestive Diseases and Sciences.1997(1)
  • 4Mine Kinoshita,Kazuya Yamasaki,Yoshio Kokusenya PhD,Hajime Tamaki PhD.Relationship between gastroprotective effect of locally acting antiulcer agent ecabet sodium and its binding to gastric mucosa in rats[J].Digestive Diseases and Sciences.1995(3)

同被引文献12

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部